PGI3 IMPACT OF DOSE ESCALATION ON TREATMENT COST OF IMMUNOBIOLOGICAL THERAPIES FOR CROHN'S DISEASE FROM THE BRAZILIAN PRIVATE PAYER PERSPECTIVE

Abstract

Authors

M.L. Rachid R. Baida C. Fioratti M.J. Brunelli T. Decimoni

Full Text Cite This Article
Back to Volume 19, Supplemental S
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×